BU-NOT-SET

CONTACT US
Overcoming oncolytic virus obstacles with the help of a CDMO partnership
  • Biologics
oncolytic virus
Insight
Webinar: Beyond borders: Navigating global scale-up for viral-based therapies
  • Biologics
webinar
Webinar
Choosing the right container for your sterile drug product
  • Drug product
eBook: How a CDMO partner helps choose the right container for sterile drug products
eBook
Cell and virus banking in OV development and manufacturing
  • Biologics
Cell and virus banking
White paper
Overcoming technical transfer challenges in virotherapy manufacturing
  • Biologics
virotherapy
Insight
Flexibility in gene therapy: Adapting to the unique gene therapy demands
  • Biologics
gene therapy
eBook
Webinar: An optimised Plasmid DNA platform
  • Biologics
Plasmid DNA
Webinar
The future of oral solid dose formulations
  • Drug substance
  • Industry trends
oral solid dose
Insight
Trends and challenges to impact the OSD space in 2024 and beyond
  • Industry trends
OSD
Insight
Insight
  • Industry trends
The outlook for a year of change
Insight
  • Drug product
Can oral solid dose keep its place as the leading dosage form?
Insight
  • Drug substance
Relocating API supply to avoid over-reliance
Case study
  • Drug product
Modified release fixed dose combination product with two poorly soluble drug substances
Insight
  • Drug product
Patient centricity during drug development and commercialisation
Insight
  • Drug product
10 considerations to kick-start your drug development journey
Insight
  • Drug product
Guidance for start-ups on drug development
White paper
  • Drug product
  • Drug substance
Drug development for start-ups
Insight
  • Sustainability
Optimising environmental sustainability